Biogen Inc. (BIIB) Earnings Call Transcript & Summary

October 20, 2021

NASDAQ US Health Care Biotechnology earnings 66 min

Earnings Call Speaker Segments

Mike Hencke

executive
#1

Welcome, and thank you for being with us for Biogen's Third Quarter 2021 Earnings Call. Before we get into it, please head over to the Investors section of biogen.com, where the earnings release is posted along with the financial tables you'll want, including our GAAP figures and a reconciliation of the GAAP and non-GAAP measures we'll be discussing today. Our GAAP financials appear in Tables 1 and 2, and Table 4 lays out how our GAAP results reconcile to the non-GAAP ones. We believe non-GAAP results give a clearer view of the underlying economics of the business and the way we manage it internally; you'll also find slides on our website that follow along with the topics covered on this call. Before we begin, please be aware that we'll be making forward-looking statements, which are based on what we currently expect and believe. These statements involve risks and uncertainties, so our actual results may differ materially. I'd recommend reviewing the risk factors discussed in our SEC filings for more information. During today's call, we'll be discussing ADUHELM. ADUHELM is approved for the treatment of Alzheimer's disease. Treatment with ADUHELM should be started in patients who have mild cognitive impairment or the mild dementia stage of the disease — the population that was studied when treatment was initiated in clinical trials. There is no safety or effectiveness data to support initiating treatment at earlier or later stages of the disease than those that were studied. This indication received accelerated approval, which was based on how much amyloid beta plaques were reduced in patients who took ADUHELM. Whether that approval continues could depend on a confirmatory trial or trials confirming the clinical benefit. There are serious side effects that ADUHELM may bring about, among them amyloid-related imaging abnormalities, also called ARIA. Though ARIA typically produces no symptoms and shows up often as a side effect, it has the potential to become serious. Serious allergic reactions are another possible result of taking ADUHELM. ARIA, headache, and fall rank among the side effects seen most frequently. Full prescribing information along with the patient medication guide can be found at aduhelm.com; our Chief Executive Officer, Michel Vounatsos, is here with me on today's call, as is Dr. Here with us are Al Sandrock, who leads Research and Development, and Mike McDonnell, our Chief Financial Officer. Joining us for the question-and-answer segment will be Alisha Alaimo, who serves as President of our U.S. Organization, along with Toby Ferguson, who heads Neuromuscular Development. <<operator_script>> At this point, I'll pass things over to Michel.

Michel Vounatsos

executive
#2

Hello, everyone, and thanks for being here today. We still saw 2021 as a year of major transformation for the company, and we feel good about what we achieved in the 2021 pipeline as well as how operations kept performing. That said, we are clearly let down by how slowly ADUHELM has been taken up in the U.S. Our third-quarter financials were strong, with total revenue reaching $2.8 billion and non-GAAP EPS coming in at $4.77. Biogen keeps executing well and showing resilience in MS, SMA and biosimilars, even with competition. Mike will walk through more of the financial specifics, while I'll spend most of my time on ADUHELM. Our belief in ADUHELM's long-term potential remains intact. During this quarter, we kept moving the U.S. launch forward while waiting for the reimbursement decision affecting Medicare patients. We are addressing the 3 near-term challenges we've outlined before, concentrating mainly on getting patients access. It's important to note that we've achieved consistent progress on key metrics, yet the health care system is still a significant bottleneck. Specifically, uncertainty around reimbursement has held up patient access to the first therapy targeting an underlying pathology of Alzheimer's disease, which is reasonably likely to predict clinical benefit. We await the forthcoming Medicare national coverage determination, anticipated by next April, which should settle Medicare reimbursement for the whole class of antibodies aimed at amyloid. The NCD is a thorough process with multiple consultations, and we recognize it is necessary for this new category of Alzheimer's drugs. Still, remember that this will push back access for many patients by roughly 300 days from approval. Biogen is moving urgently on the 3 strategic priorities as we try to help patients get access. First, we're trying to deepen the community's grasp of our clinical data. As a reminder, the Phase III EMERGE study hit its prespecified primary and secondary end points, demonstrating a meaningful decrease in clinical decline. Patients on high-dose ADUHELM saw meaningful gains on measures of cognition and function, such as activities of daily living. While the other Phase III trial, ENGAGE, missed its primary end point, analyses of both studies showed that greater exposure to ADUHELM corresponded with larger reductions in clinical decline. These Phase III findings have gone to a top-tier journal, and a manuscript is now undergoing peer review, alongside other publications of our data. We'll keep producing more data too. We started ICARE AD, the first real-world observational Phase IV study in Alzheimer's disease, intended to assess the safety and effectiveness of ADUHELM in clinical practice. A draft protocol for the required Phase IV confirmatory study has been sent to the FDA. This study has full resourcing, and we aim to finish it ahead of schedule. Along with sharing ADUHELM data during this year's AAIC meeting, baseline results from EMBARK have been cleared for presentation at CTAD next month, and those should give us valuable insight into how a treatment gap matters. On top of that, we intend to share key new plasma phosphorylated tau findings from EMERGE and ENGAGE, which shed light on aducanumab's downstream effect, as quickly as we can. All told, ADUHELM's approval rested on a substantial body of evidence drawn from 8 studies involving over 3,000 patients, and we're eager to keep producing further data that backs up ADUHELM's clinical profile. Priority number two for us is giving proper support to building out the infrastructure that's needed. When we launched, we set up a program alongside Labcorp and Mayo Clinic Laboratories for amyloid beta CSF testing. Over the course of the quarter, the count of patients making use of that program kept climbing. We likewise kept pushing for amyloid PET imaging to be reimbursed. Beyond that, additional sites keep coming online — roughly 120 sites are now treating patients with ADUHELM, and plenty more are in the pipeline. Third, so that reimbursement is clearer while we await the NCD decision covering this antibody class, we've secured the permanent ADUHELM J-code, which takes effect in January of next year, and we're hopeful it will make the coding process less complicated for health care providers. Going forward, besides presenting and publishing the data I just described, the biggest near-term milestone will be how the NCD for antibodies targeting amyloid turns out. A draft decision should arrive in January, with a final decision to follow in April of 2022. On the broader Alzheimer's front, our partner Eisai has lately kicked off the FDA rolling submission for the lecanemab BLA through the accelerated approval pathway, after receiving Breakthrough Therapy Designation in the U.S. Among anti-amyloid antibodies that are approved or in late-stage development, Biogen and Eisai have a chance to give patients 2 of the 4 possible options. With the first FDA-approved therapy targeting an underlying pathology of Alzheimer's disease, the prospect of delivering lecanemab, promising tau pipeline programs like BIIB080, and the advantages of digital technologies, we think Biogen is well positioned to stay a long-term leader in Alzheimer's disease. Turning away from Alzheimer's disease, alongside our partners at Sage, we keep advancing toward delivering potential novel therapeutic options for patients who suffer from depression. We lately gained positive data from a Phase II study in Japan — the third positive placebo-controlled study for zuranolone in MDD. We also made public our plans to start a filing in the U.S. Finally, we recently shared data from the VALOR Phase III study of tofersen in ALS. While the VALOR study missed its primary end point, signs of reduced disease progression showed up across multiple end points. The totality of the evidence encourages us, and we're in discussions with regulators about next steps. After talks with trial investigators and bioethics specialists, and after hearing what patient advocacy organizations had to say, our plan is to widen the early access program so it reaches the larger group of people who are living with SOD1-ALS. In our view, these recent developments mark a major move ahead toward our aim of remaking Biogen from a business that was once focused on MS into one founded on a portfolio of multiple franchises spanning a wide range of neuroscience therapeutic areas. At this point I'd like to hand the call over to Al, who will give a more detailed update on how our R&D work is progressing.

Alfred Sandrock

executive
#3

Thank you, Michel, and good morning to all of you. As I always do, I want to begin by expressing my appreciation to the Biogen team for the effort they've put in as we keep moving our R&D programs forward. Beyond the important readouts in major depressive disorder and ALS, we held an R&D Investor Day to share information with you regarding our pipeline programs, our research capabilities and our expertise. I'd urge you to review those presentations, which are available on our website. Let me begin now with Alzheimer's disease, starting with aducanumab. During the R&D Day presentation earlier this month, I emphasized how important it is to establish the link between drug and biology, and likewise between biology and disease, throughout the drug development process; in late June, the FDA made data from the ADUHELM drug approval package available to the public. Some of those key relationships are addressed in the clinical pharmacology review contained in the approval package, as the next 2 slides illustrate. On this first slide, you can see the relationship between amyloid plaque burden, measured by the observed SUVR score, and drug exposure, measured by the predicted cumulative AUC, both at week 78, incorporating all of the data from both Phase III trials of aducanumab. Across the 2 studies, the relationship between aducanumab exposure and amyloid plaque reduction is consistent, and it demonstrates that amyloid plaque burden goes down as cumulative drug exposure goes up. Another figure from that same document appears on the next slide, plotting the relationship between the reduction in amyloid plaque burden, as measured by SUVR, and the preservation of clinical function, as measured by the CDR Sum of Boxes, across multiple dose levels of several anti-Abeta antibodies. In the ADUHELM label, Studies 301 and 302 are called Study 2 and Study 1, respectively. Taken together, these data from 6 different anti-amyloid antibodies demonstrate an association between amyloid plaque reduction and a reduction in clinical decline; and they show that larger amounts of amyloid plaque reduction are required in order to achieve a reduction in clinical decline. At the annual AAIC meeting in July, we presented additional data from the EMERGE, ENGAGE and PRIME trials, which demonstrated that treatment with aducanumab produced a reduction in amyloid plaques as well as downstream biomarkers of Alzheimer's disease pathophysiology, and that this likewise produced a slowing of clinical decline. We look forward to presenting further data from our aducanumab trials, among them the baseline data from the EMBARK study, at the upcoming CTAD meeting next month in Boston. We also look forward to presenting, at the earliest possible opportunity at a scientific venue, new data on plasma P181 tau, reflecting the downstream biological and clinical effects of aducanumab, which I believe scientists and clinicians will find of great interest. As a reminder, the defining pathophysiologic features of Alzheimer's disease are amyloid plaques containing Abeta protein and neurofibrillary tangles containing phosphorylated tau. Lastly, I'm pleased to report that we remain on track to publish the Phase III aducanumab trial results soon in a major peer-reviewed journal. During this quarter, we also handed over a draft protocol to the FDA for the mandatory Phase IV confirmatory study of aducanumab. As I've mentioned previously, the trial has been given all the resources it needs, and our objective is to finish it before the planned timeline. One central aim of this confirmatory research is making certain we bring in suitable numbers of Alzheimer's disease patients from groups that are underrepresented. Projections indicate that by 2030, close to 40% of all Americans who have Alzheimer's disease will be African American or Latinx, so securing adequate involvement from these communities matters greatly in order to mirror how this illness appears across the real-world population. By means of the Phase IV confirmatory study, along with ICARE AD, our goal is to deliver additional evidence regarding the clinical benefits and risks tied to treating with aducanumab. Beyond the United States, we are undergoing regulatory review in several regions, among them the EU, where we are busy getting ready for a scientific advisory group meeting that forms part of the CHMP review process. Now shifting to lecanemab. We eagerly anticipate the moment when we might be able to offer 2 anti-amyloid antibody choices for patients with Alzheimer's disease. As was previously stated, our collaboration partner, Eisai, has lately begun a rolling submission to the FDA of the lecanemab data, seeking possible accelerated approval. We anticipate that this submission will wrap up at some point during 2022. Moving on to MS. Last week, at the annual ECTRIMS meeting, we shared new data, which included: primary results from the NOVA Phase IIIb study assessing how well TYSABRI extended interval dosing works compared with the approved every 4-week dosing; a real-world, claims-based analysis of relapse and hospitalization rates among MS patients given natalizumab versus ocrelizumab; a fresh analysis of the EVOLVE-MS-2 data centered on how dose titration affects the GI tolerability of VUMERITY relative to TECFIDERA; and data from MS PATHS revealing that 100% of people with MS treated with natalizumab, interferons or fumarates mounted an antibody response after COVID-19 vaccination, in contrast to 40% of MS patients receiving anti-CD20 or S1P therapies. Regarding the launch of VUMERITY in the EU, we were pleased to hear about the approval in Switzerland, as well as the positive CHMP opinion, and we look forward to the final EMA decision. In neuropsychiatry, we were thrilled to see results from the Phase II study of zuranolone in major depressive disorder that Shionogi recently finished. That Phase II trial had a design comparable to the other studies looking at zuranolone and MDD, and it compared 20 and 30 milligram doses of zuranolone against placebo in Japanese patients with MDD. Findings from this study lend further backing to the safety and efficacy profile of zuranolone, since it showed rapid onset along with significant reductions in the HAM-D17 score at day 3, day 8 and day 15. Moreover, although it did not reach statistical significance, we observe separation from placebo for both the 20 and 30 milligram zuranolone treatment arms out to day 57. Every adverse event seen in the trial was mild to moderate, and they matched what we already know about zuranolone's safety profile. The Shionogi trial has become the third double-blind, placebo-controlled study of zuranolone in MDD in which the primary end point — change in the HAM-D score at day 15 — was achieved. These MDD findings come on top of zuranolone's efficacy in PPD, which we saw in the ROBIN study. Because the results have been consistent across the zuranolone trials, Biogen and Sage have announced they plan to submit an NDA to the FDA in the second half of 2022. That planned initial submission package will be used to seek approval of zuranolone for treating major depressive disorder, and we anticipate an additional filing for postpartum depression in the first half of 2023. In addition, the CORAL study, which is designed to evaluate zuranolone as an acute rapid response therapy when it is co-initiated with standard antidepressant therapy, is now fully enrolled, with top line data expected in early 2022. Now moving to neuromuscular disorders. Earlier this week, we announced results from the pivotal Phase III study evaluating tofersen in people with SOD1-mediated ALS. The Phase III study, or VALOR study, used a study-enrichment approach to stratify participants into faster and slower progressing cohorts.

Alfred Sandrock

executive
#4

We obviously didn't get the news we wanted: the trial failed to hit its primary endpoint, which required a statistically significant shift from baseline to week 28 on the ALS Functional Rating Scale within the faster-progressing group. Even so, we saw encouraging signals that favored tofersen on a number of secondary and exploratory measures of biological and clinical activity, covering motor function, respiratory function, muscle strength and quality of life. On top of that, a prespecified pooling of data from the Phase III study and its ongoing open-label extension strengthened these results, showing that starting tofersen earlier resulted in a slower decline on those measures. Outside the clinical measures, we saw decreases in CSF SOD1 relative to placebo, which points to target engagement having been achieved. Also, on the key secondary endpoint — a change in plasma neurofilament light, a possible marker of neuronal degeneration — we saw reductions of 67% among faster-progressing patients and 40% — 48% among slower-progressing patients on tofersen versus placebo. As far as we know, these are the largest drops in plasma neurofilament levels ever seen in an ALS clinical trial. The majority of adverse events in the Phase III study were mild to moderate, and many matched ALS disease progression or events related to lumbar puncture. Some patients on tofersen experienced serious adverse events, including transverse myelitis. Given what the Phase III study showed, we're actively working with regulators, the medical community, patient advocacy groups and other key stakeholders globally to figure out next steps for tofersen. In addition, after talking with leading medical experts and ethicists, we intend to give all eligible SOD1-ALS patients early access to tofersen via an expanded access program. Because treating SOD1-ALS early may matter a great deal, we kept enrolling patients in the ATLAS study, a Phase III trial of tofersen in clinically presymptomatic carriers of SOD1 mutations. We hope that treating people sooner in the disease could offer the best chance to slow or even postpone the onset of this awful disease; also, in neuromuscular disorders, this quarter we announced plans to launch ASCEND, a Phase IIIb study, intended to assess whether an investigational higher dose of nusinersen can improve clinical outcomes for patients who were previously treated with risdiplam. Our SPINRAZA data show that exposure stays similar as patients get older and grow. We're also moving forward with the ongoing DEVOTE study, which evaluates the safety and efficacy of higher exposures of SPINRAZA, since our preclinical work suggests we should be able to raise its dose safely; through DEVOTE and ASCEND, we hope to further inform SMA treatment and tackle the unmet needs that remain for patients. To sum up, as I said at our recent R&D Investor Day, we believe the science is breaking and that now is precisely the right moment to be pioneers in neuroscience. Drawing on a thorough grasp of human genetics and disease biology, our efforts aim to bring about the coming era of neurotherapeutics — one in which we pinpoint the correct patients and intervene early, possibly even ahead of symptoms appearing, so that we can substantially slow, or perhaps stop, the advance of disease. At this point I'll hand the call to Mike.

Mike McDonnell

executive
#5

Al, thank you. Our performance in the third quarter has us quite encouraged, since we kept executing at a high level. Going forward, our attention stays entirely on the primary business, which includes bringing ADUHELM to market across the United States. Third quarter total revenue came to $2.8 billion, a drop of 18% from the same period a year earlier on both an actual and a constant currency basis, and that figure captures what TECFIDERA generics have done to us. Multiple sclerosis revenue overall reached $1.8 billion in the third quarter, and that includes OCREVUS royalties. Let me turn to a few specific MS products. TECFIDERA worldwide revenue during the third quarter was $499 million. Within the United States, revenue of $179 million for the quarter was level with the quarter before, since reduced volume was offset by smaller discounts and allowances; looking ahead, we anticipate U.S. TECFIDERA revenue will fall. Beyond the United States, TECFIDERA brought in $319 million in the third quarter, up 13% from a year earlier, helped by 7% growth in underlying patients. We felt good about VUMERITY's ongoing climb, from $91 million in the second quarter up to $121 million in the third quarter. It also pleases us that VUMERITY won a positive CHMP opinion in the EU and gained complete regulatory approval in Switzerland. TYSABRI's worldwide third quarter revenue hit $523 million, a rise of 1% year over year, despite some unfavorable channel dynamics in the United States. We welcomed 7% growth in TYSABRI patients globally; in our view TYSABRI is well placed to take on a growing role in treating MS, through efforts such as subcutaneous administration and extended interval dosing; the fresh COVID vaccination data Al referenced also gives us encouragement. Turning to SMA. SPINRAZA worldwide third quarter revenue was $444 million, down 10% from the prior year. U.S. SPINRAZA revenue of $140 million fell 23% year over year, reflecting ongoing competitive pressure. Still, we took encouragement from the fact that discontinuations came in lower than in this year's second quarter. Beyond the U.S., SPINRAZA revenue dropped 2% from a year earlier because of competition and pricing pressure in Europe, partly offset by growth in regions outside Europe. Keep in mind that SPINRAZA revenue outside the U.S. during Q1 and Q2 2021 gained from accelerated shipments. Given overall market growth, ongoing data generation, the efficacy and safety profile across all age groups, and further geographic expansion, our belief remains that SPINRAZA can get back to growth in the medium to long term. ADUHELM revenue for the third quarter totaled $300,000, as wholesalers steadily worked down inventory they had bought in Q2. Uptake has been delayed for the 3 main reasons Michel covered. I'd point you to this slide, along with slides in the appendix, for specifics on the accounting with Eisai and Neurimmune, which varies by geography. Now let's move to our biosimilars business. Revenue for the third quarter came in at $203 million, which was a 2% decline from the same period a year ago, as pricing pressure and the COVID-19 pandemic kept weighing on us. We're thrilled that BYOOVIZ has received approval in the U.S., EU and U.K., and we see a chance to keep expanding our biosimilars business through launching new products and moving into additional geographies like the U.S. Anti-CD20 revenue overall for Q3 totaled $415 million, a 26% drop from the prior year, and that decrease was mainly the result of lower RITUXAN revenue amid ongoing biosimilar competition, something we anticipate will persist. Total other revenue for the third quarter reached $158 million, up 26% year over year. Other revenue during the quarter got a boost from the timing of shipments tied to contract manufacturing. Gross margin for Q3 was 82% of revenue, a modest decline from 83% in the previous quarter and a drop from 87% in Q3 of 2020. The year-over-year gross margin contraction stemmed largely from lower TECFIDERA and RITUXAN sales, since both are high-margin products. We anticipate gross margins will keep facing downward pressure ahead. Turning to expenses and the balance sheet. Non-GAAP R&D expense for the third quarter was $702 million, which encompassed a $125 million upfront payment tied to our collaboration with InnoCare. Non-GAAP SG&A came to $651 million, with roughly $135 million of that related to ADUHELM. Keep in mind that starting in the second quarter, Eisai's reimbursement of U.S. SG&A costs shows up in the collaboration profit sharing line. Collaboration profit sharing in the third quarter was a net expense of $21 million, which reflects a $51 million reimbursement from Eisai connected to ADUHELM's commercialization in the U.S. Our effective non-GAAP tax rate for the quarter was about 14%, compared with roughly 19% in the third quarter of last year. Non-GAAP loss attributable to noncontrolling interest in the third quarter was $11 million. As a reminder, ADUHELM royalties and commercial launch milestones paid to Neurimmune will appear in this line. Eisai's reimbursement for those items will appear in collaboration profit sharing. During the quarter, we bought back 2.2 million shares of the company's common stock for $750 million. As of September 30, 2021, $2.8 billion was left under the share repurchase program authorized in October of 2020. Our weighted average diluted share count for the quarter was approximately 149 million shares. Non-GAAP diluted earnings per share in the third quarter was $4.77; during the third quarter, we produced approximately $805 million in cash flow from operations. CapEx was $42 million and free cash flow was approximately $763 million. We closed the quarter with $7.3 billion in debt, $3.9 billion in cash and marketable securities and $3.3 billion in net debt. Additionally, our $1 billion revolving credit facility was undrawn as of the end of Q3. All told, our finances are quite solid, with plenty of cash and the wherewithal to expand the company over the long haul. Now let's discuss the revised outlook we have for the entire 2021 fiscal year. For the whole of 2021, we're raising our revenue projection; it had been $10.65 billion to $10.85 billion, and now it sits at $10.8 billion to $10.9 billion, largely because MS did better than expected. Our non-GAAP diluted EPS forecast is moving up as well, from the earlier $17.50 to $19 range to a fresh $18.85 to $19.35 range, with the main driver being the extra revenue I just described. Meanwhile, we're bringing our capital expenditure outlook down; it was $375 million to $425 million, and it's now $250 million to $300 million, chiefly because spending on certain projects has slipped, some of them affected by COVID-19. Built into our guidance is the assumption that ADUHELM brings in very little revenue during 2021. Our expectation remains that revenue will begin building in 2022 and later years, especially following the NCD decision in April, provided the outcome is favorable. We anticipate that TECFIDERA and RITUXAN will keep declining within the U.S., and that the lost sales from these high-margin offerings will weigh on our gross margin percentage. For the full year, non-GAAP R&D costs should land somewhere between $2.45 billion and $2.55 billion. That figure matches what we told you before. For the full year, non-GAAP SG&A costs should come in somewhere between $2.6 billion and $2.7 billion; that figure likewise matches our earlier guidance and factors in an ADUHELM investment of roughly $500 million. Out of that sum, about $150 million is reimbursable from Eisai, shown as collaboration profit sharing starting April 1 rather than being counted in SG&A. These ADUHELM outlays come in a bit below what we had previously estimated, and naturally we'll keep actively controlling how quickly this money is spent; this yearly SG&A range additionally presumes heavier spending in Q4 due to seasonal patterns, just as in prior years. For additional key guidance assumptions, please see our press release. To wrap up, we're quite happy with how we performed financially and are sharply focused on the ADUHELM launch. Our finances stay quite solid, with ample cash, limited leverage and an operation producing substantial free cash flow; in our view, these factors leave us well placed to keep expanding the company over the long haul. At this point I'll hand the call back to Michel for his closing remarks.

Michel Vounatsos

executive
#6

Thanks, Mike. In this year's third quarter, Biogen kept showing its ability to weather challenges and execute well, which gives the company a solid base as we move forward with the ADUHELM launch before the key data readouts and publications, along with the NCD decision for the anti-amyloid antibody class expected next April. We see ADUHELM as a major advance in the battle against Alzheimer's disease, since it is the first FDA-approved therapy targeting a defined pathology of the disease that is reasonably likely to predict clinical benefit. We recognize that patients are suffering from this disease right now, and those patients stay in our minds as we strive to support access. In fact, at next month's CTAD meeting, we will present an analysis demonstrating that, absent access, we estimate that each passing day more than 1,000 Americans shift from mild to moderate Alzheimer's dementia and thus may no longer be suitable for starting treatment with ADUHELM. As many people have noted, our current system thus far does not do enough when it comes to diagnosing and intervening in this disease. Moreover, Alzheimer's disease is a particularly severe matter of inequity, since African Americans are up to 3x more likely and Latinx individuals are 1.5x more likely to have Alzheimer's disease relative to others. We grasp how serious this problem is, and that inclusion of underrepresented populations in drug development is frequently low, including in our Alzheimer's clinical trial. We also recognize that there is work for us to do and a role for us to play in fixing this. Therefore, the design of ICARE AD, our real-world Phase IV observational study of ADUHELM, seeks to include at least 16% of the trial's expected enrollment from Black, African-American and Latinx patients. To close, I want to thank our employees worldwide who have shown their commitment to making a positive difference in patients' lives, as well as all the physicians, caregivers and participants in our clinical development programs. Our capacity to bring medicines to patients would not be possible without their passion and dedication. We will now open the call for questions.

Robyn Karnauskas

analyst
#7

Many of us, I believe, have been wrestling with certain headlines originating from physicians regarding their reluctance to prescribe this medication. And I recognize that you are pointing to the NCD — the absence of a decision on the NCD — as the central issue behind the absence of reimbursement. However, could you speak a bit about how you intend to persuade physicians, should you secure a favorable NCD decision, to administer this drug to patients? And is this something that — we are observing it in the headlines. Is this something you are contending with? Is it a major obstacle to adoption of the drug?

Michel Vounatsos

executive
#8

Without question, Robyn, it — in fact, our foremost objective is essentially to inform the community, drawing on supplementary data, on the data already shared plus further data that we will share and publish soon. They likewise anticipate a complete publication in a peer-reviewed journal. And at times, this gets raised, yet another concern is the monetary exposure stemming from the lack of NCD coverage. Therefore, these matters are connected. I'll invite Alisha to elaborate a little.

Alisha Alaimo

executive
#9

Absolutely. Michel, I appreciate it, and Robyn, thanks for raising that. Honestly, there's no precise formula here. What we're seeing, and what we keep hearing, is that most prescribers land in some mix of 2 buckets. One revolves around the benefit/risk profile — which naturally ties to what you've been reading and what the question touches on. The other is what we call hesitancy stemming from the NCD analysis. That said, a substantial share of prescribers remain on the fence. Some of them show up in the headlines. We've got quite a big group that hasn't landed on either side yet. That's exactly why several teams are at it daily, putting in serious effort to help educate sites and HCPs about our clinical data and about the reimbursement pathways, which as you're aware are quite complicated; Michel brought that up too during his opening remarks, but we're pushing with urgency since the price of inaction is something everyone grasps. Michel also noted our estimate that 1,000 patients per day move forward in their Alzheimer's journey, going from mild to moderate AD, and they might not be suitable for ADUHELM any longer. So we genuinely want to be part of the answer, and that drives us daily. The moment we have additional data, we'll share it, because we get where the question is coming from. Thank you.

Michel Vounatsos

executive
#10

Robyn, our view is that proof — not just from adu, but possibly from additional anti-amyloid treatments too — is going to add up to a considerable collection of evidence for people who, for years now, have been either adopting or questioning the amyloid hypothesis. On top of that, the results we've seen for ADUHELM give us a lot of encouragement. Our confidence in what our data shows hasn't wavered at all; that's exactly why it appeared in the script 2 or 3 times. There's more ahead.

Michael Yee

analyst
#11

I realize you said the NCD is obviously a key milestone, but could you share your perspective on what the possible scenarios might look like? Also, what would you consider a favorable NCD result? And within that favorable result, how significant would PET reimbursement be?

Michel Vounatsos

executive
#12

Thanks, Mike — and Michael; as you're aware, for quite a few months now we've been pushing for PET reimbursement. Alisha will give you additional detail regarding the various possibilities. Alisha, what about the NCD?

Alisha Alaimo

executive
#13

Absolutely. Michel, I appreciate it, and Michael, thanks for raising that. It's key to keep in mind, as we've said before, that NCD applies not just to ADUHELM, correct? This covers the whole category of monoclonal antibodies aimed at amyloid for treating Alzheimer's disease. We can't really guess what the NCD analysis will conclude; but as you're aware, our view is that it's going to be a significant milestone, and it should clear up a great deal of the perplexity physicians are encountering. That said, 5 possible results exist. And I'd say the 3 that get discussed most often or draw the most attention are, first, a decision of no coverage. The second would be coverage with evidence, known as CED. And then there's coverage with restrictions. If you examine the record and look back across the past 20 years, just 12 have been through this kind of review. One involved noncoverage. One was an off-label situation for a CED, and the remaining 10 were essentially covered indications. So while we truly can't weigh in on it, we're inside this demanding process. We respond to them whenever they require more data, but bear in mind that every manufacturer is going through this alongside us.

Cory Kasimov

analyst
#14

So I realize everyone is holding out for the NCD. Yet at this point in the launch, with initial traction having been so tough, is any thought at all being given to adjusting ADUHELM's gross price? Or would you say that isn't a major obstacle here?

Michel Vounatsos

executive
#15

In my view, the NCD matters greatly. Getting the data out there matters even more, and each of those two things ties into the other. And as we review the metrics, the strategic metrics, the market research, price simply isn't showing up as the top concern. Our rationale is solid. On ICER's assessment, we plainly reject its foundational premise regarding proper pooling of data, its downbeat assumptions about long-term efficacy, and much else besides. And I doubt we're alone on that within the industry, all right? So of course, we retain the ability to make refinements to our pricing, and we hold onto that as an option. But data comes first, and data is tied, obviously, to the NCD decision. Meanwhile, infrastructure is moving forward too. Alisha, would you like to offer feedback on the price question?

Alisha Alaimo

executive
#16

Absolutely. Michel, thank you — and Cory, thanks for raising that. Michel is completely correct on this point. Price certainly matters a great deal to sites and to patients, but what I can tell you is that nobody has told us cost is the main reason behind any choice not to treat someone. The real obstacles we're up against are exactly the ones Michel described — the same ones you read about in the media daily and likely encounter while preparing your analyst reports. Still, as is true with other therapies, when patients worry they may struggle to pay for ADUHELM, we offer financial assistance programs designed to help them. So should reimbursement or affordability become issues of concern, our hope is that these programs can serve as a genuine route forward for them. We firmly believe that lacking financial resources ought not to stand as an obstacle preventing patients from getting ADUHELM.

Michel Vounatsos

executive
#17

And what matters here, Cory, is that you'll recall how, when we launched on day 1, we handed things over to decision makers for the innovative contract — covering price volume, among other things — and we did so voluntarily, with the goal of securing sustainability. And keep in mind, this isn't 6 million patients, nor even 1 million to 2 million. It's a subset of those who will be treated gradually. So we made that offer, and both decision makers and CMS know about it. But at this point the NCD process is what's in play, so we're stepping back and honoring that process; the offer, though, remains on the table.

Marc Goodman

analyst
#18

I'd like to ask about zuranolone. If we go ahead with this as a 2-week course of treatment, that suggests a fairly substantial cost for each pill. And really, it would amount to an all-in approach and a major shift in how depression gets treated, which strikes me as somewhat risky. I'm simply wondering about the market research your company has conducted and the discussions you've held with psychiatrists, to establish that they're on board and that this approach is sound and will truly deliver results. Clearly, the product acts quite fast, which matters on its own, but a 2-week treatment course would be very, very unusual.

Michel Vounatsos

executive
#19

What matters is that, in the end, we'll be able to change how major depressive disorders and postpartum depression are managed. At present, science readouts and the extra data we receive are what guide us. I have to say that a conversation about price hasn't happened yet. Well, I'm aware the team is beginning to generate data and market research evidence so that we'll be prepared if the data support it, but we're happy with the 3 placebo-controlled results all pointing the same way. Al?

Alfred Sandrock

executive
#20

Absolutely, Marc. This represents a true paradigm shift and requires psychiatrists to adopt a completely different mindset. Consequently, a great deal of education will be needed, provided we secure approval. The way I see it, SSRIs or SNRIs constitute the present standard of care. Those medications require weeks, perhaps over a month, before they take effect; afterward, patients remain on them long term, frequently experiencing side effects. That is hardly an ideal scenario. What keeps people on these drugs long term is their slow onset of action; therefore, offering a 2-week treatment course, after which the drug can be taken as needed, amounts to a very different mindset, and I believe many treating physicians would find it appealing. Since it works rapidly, this allows the 2-week treatment to be given and then the next as-needed treatment to be awaited. That is because physicians know, and can be reassured, that within 3 days of starting, they observe efficacy — they will observe efficacy in their patients. So it is indeed a different mindset, yet I find it very, very exciting.

Matthew Harrison

analyst
#21

Al, I'd like to hear your thoughts, and could you also give us a refresher on what sets the BAN2401 Phase III study apart from the ADUHELM studies? The backdrop for this question is: how crucial do you believe a positive Phase III result for BAN2401 will be next year, particularly when it comes to shifting how physicians view ADUHELM and anti-amyloid therapies?

Alfred Sandrock

executive
#22

Yes. Matthew, I'd say it matters a great deal, since, as has been mentioned already, there's uncertainty among doctors regarding the benefit/risk. And like Michel noted, the information emerging not just from aducanumab, but from every one of these anti-Abeta antibodies that are alike in their capacity to substantially lower amyloid burden, is going to carry a lot of weight. What about the differences? Aducanumab and lecanemab have more in common than they have apart. Each of them attaches to aggregated forms of Abeta. Each achieves a fairly large reduction in amyloid plaque burden. Where they diverge: lecanumab requires no titration, and right now the ARIA rates appear to be low; the Phase III study will give us the answer, but they appear lower than what's seen with aducanumab; and dosing happens once every 2 weeks. So — and keep in mind, to address your question, the Phase III trial's design closely mirrors that of the aducanumab Phase III trials. As an illustration, CDR-Sum of Boxes serves as the primary end point, and that's the recognized clinical efficacy measure for this condition.

Geoff Meacham

analyst
#23

This is Geoff. I have another one about ADUHELM. Before it got approved, you folks mentioned you'd be expanding manufacturing capacity and spending quite a bit on the commercial side of the launch. So I suppose what I'm asking is whether that plan has shifted, considering how slowly things have rolled out. I'm trying to figure out if this is more of a wait-and-see situation ahead of the April NCD, or if you'll keep being aggressive with the money you're putting into the ADUHELM launch.

Michel Vounatsos

executive
#24

Thanks, that's a great question. As a company, we stay the course, obviously, since it's as though we're in a delayed prelaunch — an extended prelaunch period ahead of the launch — and we stay the course. Of course, we're pacing the spending quite carefully. Mike, the team, and I are examining the investment requests that come in from everywhere around the globe; so we intend to be very watchful, and that's what we are. Yet we stay the course, since we truly have faith in our data. We truly have faith in more data that's on the way, and we truly have faith that the system will adapt. And it's simply a question of a bit of time. On the slide that was shown, you saw there's a clear process. We're not far off from being there. So we stay the course. Mike?

Mike McDonnell

executive
#25

Absolutely, Geoff — that's a solid question. What I'd call it is a gating approach. Our confidence in ADUHELM's potential over the long term hasn't changed. That said, given the delays we've seen, the plan is to gate our spending. We're still putting in a substantial amount — roughly $500 million in SG&A, or about $350 million net of reimbursement for 2021. On the CapEx side, a portion of that is tied to facilities supporting ADUHELM, and we're gating that as well. The bulk of the decrease in our CapEx guidance comes down to timing, and on top of that, we're currently dealing with a somewhat strained global supply chain. So our approach will be prudent — we'll gate — yet we'll stay prepared for the right moment and invest aggressively, while also being careful and gating along the way.

Michel Vounatsos

executive
#26

So it's in a prelaunch phase of sorts — an extended one — yet the momentum we're seeing gives us reason for optimism. We now have 120 centers that list ADUHELM in their formulary, which is over twice what it was a month back, Alisha. So progress is substantial. And should certain big institutions have said no and asked for additional data, we will be present there within a few weeks. So this is a process that, regrettably, is stretching out beyond what we anticipated, but we must stay resilient. And the message we intend to convey is that our confidence comes from knowing the data and witnessing the progress; it's simply going to take a little time.

Umer Raffat

analyst
#27

I'd like to break this into two pieces, if I may. To start, Mike and Michel, the remarks you gave were really helpful for those of us trying to build a model around ADUHELM for the rest of 2021. That said, the Street still has $1 billion in U.S. ADUHELM sales baked in for 2022, and that figure basically points to more than 75,000 new starts on ADUHELM in the U.S. next year. A lot of people would say 75,000 new starts next year is likely too aggressive. But since we're trying to level set today, I guess the question is whether 25,000 new starts next year would be too high an expectation. Michel, one more thing—as we get closer to the BAN2401 PDUFA, it seems like there wasn't much conversation between Biogen management and The Street before ADUHELM's pricing came out. So I'm wondering: should the Street reasonably expect a BAN2401 price that lines up more with older Alzheimer's medications?

Mike McDonnell

executive
#28

Umer, I'll handle the first part of that. We aren't providing 2022 guidance right now, but a couple of points: we did state that we anticipate minimal revenue for the remainder of 2021. Assuming the NCD goes through, we still anticipate revenue to ramp up in 2022 — that would happen in April. So that gives you an idea about Q1. Things are somewhat stalled until that point. Since we lack strong insight into patient numbers, we choose not to discuss them in public. But we did share this much: the sites keep moving forward. Right now, roughly 120 locations have treated at least one patient with an infusion. That's over twice the number from around six weeks back. We'll keep watching those figures and increase pace as fast as possible, though the various components involved mean things do slow down somewhat. Another key point to keep in mind is titration. If we complete an NCD successfully, patients still need to be titrated and doses increased over time. That means revenue will build up slowly. The key point, though, is that we still see this as a substantial opportunity worth billions of dollars over the long run.

Michel Vounatsos

executive
#29

Our view is that adoption will definitely pick up speed once the system gets a signal of possible reimbursement in January, followed by the definitive ruling in April. That said, my expectation is not for an explosive level of uptake. Nor do I anticipate a straight-line pattern. What we foresee is a nonlinear quickening of adoption, since the path a patient travels remains lengthy. And although we are achieving enormous strides, and past those 120 centers, hundreds more are moving toward getting the product listed. This is truly a step-by-step affair; however, we will not disclose additional details right now regarding how many patients, though we will get a chance to revisit this.

Mike McDonnell

executive
#30

Right. As for what BAN will cost, that's clearly a decision we'll make when the moment is right, and we intend to approach it carefully. At this point, I don't think there's much further we can add. Still, the process keeps moving forward, and the start of the rolling submission has us pleased.

Ronny Gal

analyst
#31

I have a question regarding how ADUHELM and lecanemab compare. Looking at Slide 10 of your presentation, lecanemab appears to deliver at least the same level of benefit as ADUHELM. Since this drug is expected to have a fully positive pivotal readout — presumably positive in Q3 of next year — it's a safer product, and it's actually the one you're advancing into presymptomatic Alzheimer's. I'm curious: when you describe ADUHELM as your longer-term growth driver, are we essentially talking about a choice between ADUHELM and BAN2401? Could you discuss the comparative dynamics between the 2 products? And is it possible that BAN2401 ultimately becomes the leading Alzheimer's product that Biogen sells in future years?

Michel Vounatsos

executive
#32

We're very pleased to see lecanemab progressing well, with a substantial dataset following ADUHELM — over 600 patients. However, that's just a Phase II study, so we still need to see the Phase III; nonetheless, it's quite encouraging and supports the underlying mechanism of action and the signals we're seeing. We'll have both the chance and the advantage of holding 2 assets. More importantly, let me emphasize again that we remain confident in the ADUHELM data, because we know those data, we've reviewed them, and we're seeing new data as well. And we have strong confidence in the profile and the benefit-risk of these products over the long term. With leca now, our position is even stronger, though we must await further data. Al?

Alfred Sandrock

executive
#33

Yeah, that's right. From what I've seen, results can appear extremely promising following Phase II at times. Yet once you reach Phase III, the trial is bigger, involves additional sites and more nations. So I suppose only time will reveal how it plays out. After that, naturally, the label comes through. So I'm with Michel on this.

Salim Syed

analyst
#34

Thank you. My question concerns ADUHELM. Looking at peak sales projections for ADUHELM, the sell side on The Street seems to be putting together models of around $9 billion at peak for this launch. From what I can work out, that figure rests more heavily on the drug being given chronically and used on an ongoing basis. Yet if we factor in items such as coverage with evidence, plus the possibility that this product — and I think your team has said as much — is no longer suitable for moderate patients, and that such patients could account for a sizable share of the Medicare Part B wallet, the picture changes. Should this really be seen more as a model driven by incidence, where the maximum length of coverage might be set by the NCD?

Michel Vounatsos

executive
#35

I'm not sure everyone will focus solely on incidence the way we might for SMA or HIV. Al will weigh in on that; our data still has our full support. We also think the opportunity over the long run is considerable for creating value; with competition, the market should grow, and given how large the epidemiology is, four players can fit, and we are two of those four. It's also a worldwide effort. So we're staying calm, and that's not tied to any holdup in the U.S., since a process exists there. Clearly the system isn't prepared yet — that much is visible — but there's still a great distance ahead. Al?

Alfred Sandrock

executive
#36

Yeah. I believe what's really behind your question is the idea you raised, that perhaps therapy could be halted once some amount of time has passed. Let me point you toward the lovely data my Eisai colleagues produced and presented at the AAIC, in which they took patients from their Phase II trial, and a gap in treatment occurred, and then they examined those patients in the follow-on study; and across that gap in treatment, although the burden of amyloid plaque stayed low among those whose amyloid plaque had been cleared by lecanumab, throughout that same gap, the ratio of Abeta 42 to 40 shifted gradually during that interval, which hints that biological activity tied to the amyloid pathway continues during that gap. So as I see it, whether chronic treatment is required has not yet been settled. And I think that question still needs to be investigated, and we're eager to bring you additional data on it.

Phil Nadeau

analyst
#37

I have a question regarding the locations that have gone live. You said there are 120 sites activated right now. By the time the NCD decision comes in April, what number do you expect you could have up and running? And could you also elaborate a bit on what makes getting those sites open difficult? Are those difficulties identical to what you encounter with physicians? Or do other things come into play, such as the logistics involved in ARIA monitoring or administering the infusions?

Michel Vounatsos

executive
#38

Alisha?

Alisha Alaimo

executive
#39

Absolutely, and thanks for asking that, Phil. I think if you step back for a moment and consider the activated sites — you know, those were approximately 120 or even more — and we've got several hundred more that are moving through this process, correct? So the figure we're providing refers to activated sites, meaning a single patient has received an infusion. However, it doesn't reflect every site that is working through these various stages. The operational hurdles remain unchanged. And when you truly examine this, being the first and a trailblazer in this area has been quite overwhelming for the system and for these sites. They've never had a drug like this before for their patients. And drafting their protocols, having to complete all the steps of determining where they'll perform an MRI, where — how they'll conduct the lumbar puncture and where they'll administer their infusions has been consuming their time. I spoke with a few sites just last week, and they've been attempting this since June. So it's been taking them multiple months to get operational; but when you consider our initial approach, which involved concentrating on the sites where most of our patient population has already been diagnosed, you do recall that more than 900 sites were prepared; so we think that once we, naturally, release our additional data, share our data and the NCD result is finalized, those will be the bulk of the sites that we'll keep concentrating on to get them operational and get patients through the system.

Michel Vounatsos

executive
#40

Thanks a lot for joining us on today’s call. Once again, Biogen turned in a really robust quarter. Our base business remains steady. Regarding aducanumab, meaning ADUHELM, we’re seeing some movement in spite of the near-term difficulties we’re up against. The important thing here is what lies ahead and the medium to longer term; for zuranolone, we do have a route forward. Also, we are getting ready to introduce the LUCENTIS biosimilars in the U.S. a few months from now. We really appreciate your participation on this call. It’s an exciting period at Biogen.

Operator

operator
#41

This concludes today's call. Thank you for your participation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.